English

Recro Pharma, Inc.

EDGAR

REPH Annual report amendment (10-K/A) · filed 2024-04-05

92 filing records in this dataset, filed from 2013-10-24 to 2024-04-05. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

27.7 million USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 94635000 USD Source
Revenue: 66916000 USD Source

Operating margin

6.31%

2023 Q4 · %

Exact inputs and evidence

Operating Income: -3573000 USD Source
Operating Income: -5323000 USD Source
Revenue: 94635000 USD Source
Revenue: 66916000 USD Source

Operating cash flow

1.53 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -1005000 USD Source
Operating Cash Flow: -2532000 USD Source

Free cash flow

793 thousand USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -1005000 USD Source
Operating Cash Flow: -2532000 USD Source
Capital Expenditure: 8237000 USD Source
Capital Expenditure: 7503000 USD Source

Cash and cash equivalents: 8.1 million USD 2023-12-31 Source
Exact value

8095000 USD
Long-term debt including current maturities: 39.5 million USD 2023-12-31 Source
Exact value

39472000 USD
Shares outstanding: 105 million shares 2023-12-31 Source
Exact value

104856247 shares

Reported share-count change

23.96% · 20.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

84588868 shares · 2022-12-31· Source
104856247 shares · 2023-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

94.6 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Revenue: 21527000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 21799000 USD · 2023-04-01 – 2023-06-30 Source
Revenue: 23590000 USD · 2023-07-01 – 2023-09-30 Source
Revenue: 94635000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 66916000 USD · 2023-01-01 – 2023-09-30 Source

Net income

-13.3 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Net income: -4684000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -3212000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -4592000 USD · 2023-07-01 – 2023-09-30 Source
Net income: -13274000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -12488000 USD · 2023-01-01 – 2023-09-30 Source

Operating cash flow

-1.01 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Operating cash flow: -2853000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -1628000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -2853000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -2532000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -1628000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -1005000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -2532000 USD · 2023-01-01 – 2023-09-30 Source

Capital expenditure

8.24 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Capital expenditure: 3376000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 5517000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 3376000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 7503000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 5517000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 8237000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 7503000 USD · 2023-01-01 – 2023-09-30 Source

Free cash flow

-9.24 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Operating cash flow: -2853000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -1628000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -2853000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -2532000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -1628000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -1005000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -2532000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 3376000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 5517000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 3376000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 7503000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 5517000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 8237000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 7503000 USD · 2023-01-01 – 2023-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-04-05.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2023-12-31
Operating income: 10 of 11 periods available· newest 2023-12-31
Net income: 11 of 11 periods available· newest 2023-12-31
Operating cash flow: 11 of 11 periods available· newest 2023-12-31
Capital expenditure: 9 of 11 periods available· newest 2023-12-31
Total assets: 9 of 11 periods available· newest 2023-12-31
Total liabilities: 9 of 11 periods available· newest 2023-12-31
Current assets: 9 of 11 periods available· newest 2023-12-31
Current liabilities: 9 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2023-12-31
Shares outstanding: 9 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+4.9%

Prior period

USD 90.21 million

2022-01-01 – 2022-12-31
Current period

USD 94.64 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

94635000 − 90214000 = 4421000 USD

90214000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
94635000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Year-over-year change in Revenue: 4421000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 94635000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1892575 Filing: 000095017024035480 Input fundies:Revenue: 90214000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1893945 Filing: 000095017024035480
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 6.61 million

Prior period

−USD 19.88 million

2022-01-01 – 2022-12-31
Current period

−USD 13.27 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-13274000 − -19881000 = 6607000 USD

-19881000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-13274000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Year-over-year change in Net income: 6607000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -13274000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1328050 Filing: 000095017024035480 Input fundies:NetIncome: -19881000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1261578 Filing: 000095017024035480
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.64 million

Prior period

−USD 3.64 million

2022-01-01 – 2022-12-31
Current period

−USD 1.01 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-1005000 − -3644000 = 2639000 USD

-3644000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-1005000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Year-over-year change in Operating cash flow: 2639000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1005000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1516229 Filing: 000095017024035480 Input fundies:OperatingCashFlow: -3644000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1408205 Filing: 000095017024035480
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-1.4%

Prior period

USD 8.35 million

2022-01-01 – 2022-12-31
Current period

USD 8.24 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

8237000 − 8351000 = -114000 USD

8351000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
8237000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Year-over-year change in Capital expenditure: -114000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 8237000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1417355 Filing: 000095017024035480 Input fundies:CapitalExpenditure: 8351000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1418772 Filing: 000095017024035480
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 94.64 million 100% of revenue
Operating costs Derived USD 98.21 million 104% of revenue
Operating income −USD 3.57 million −3.8% of revenue
Tax, interest and other Derived USD 9.7 million 10% of revenue
Net income −USD 13.27 million −14% of revenue

Cash

Operating cash flow −USD 1.01 million −1.1% of revenue
Capital expenditure USD 8.24 million 8.7% of revenue
Free cash flow Derived −USD 9.24 million −9.8% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Operating loss: operating costs were 113% of revenue.
2016 Operating loss: operating costs were 137% of revenue.
2017 Operating loss: operating costs were 156% of revenue.
2018 Net loss: net income was −103% of revenue.
2019 Net loss: net income was −19% of revenue.
2020 Operating loss: operating costs were 113% of revenue.
2021 Net loss: net income was −15% of revenue.
2022 Net loss: net income was −22% of revenue.
2023 Operating loss: operating costs were 104% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	51952000	58922000 Derived	-6970000	-10003000 Derived	3033000	6047000 Derived	Source 2015-01-01 – 2015-12-31: 51952000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -6970000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: 3033000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 8458000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 2411000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	69337000	95110000 Derived	-25773000	4432000 Derived	-30205000	-6972000 Derived	Source 2016-01-01 – 2016-12-31: 69337000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -25773000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -30205000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -3202000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 3770000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	71834000	112145000 Derived	-40311000	9771000 Derived	-50082000	13671000 Derived	Source 2017-01-01 – 2017-12-31: 71834000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -40311000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -50082000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 19074000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 5403000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	77347000	64866000 Derived	12481000	92204000 Derived	-79723000	3824000 Derived	Source 2018-01-01 – 2018-12-31: 77347000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 12481000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -79723000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 11022000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 7198000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	99219000	75589000 Derived	23630000	42260000 Derived	-18630000	7882000 Derived	Source 2019-01-01 – 2019-12-31: 99219000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 23630000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -18630000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 16224000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 8342000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	66499000	74841000 Derived	-8342000	19159000 Derived	-27501000	1636000 Derived	Source 2020-01-01 – 2020-12-31: 66499000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -8342000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -27501000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 9239000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 7603000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	75360000	74948000 Derived	412000	11782000 Derived	-11370000	5569000 Derived	Source 2021-01-01 – 2021-12-31: 75360000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 412000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -11370000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 10858000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 5289000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	90214000	89935000 Derived	279000	20160000 Derived	-19881000	-11995000 Derived	Source 2022-01-01 – 2022-12-31: 90214000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 279000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -19881000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -3644000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 8351000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	94635000	98208000 Derived	-3573000	9701000 Derived	-13274000	-9242000 Derived	Source 2023-01-01 – 2023-12-31: 94635000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -3573000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -13274000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -1005000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 8237000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 94.6M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	51952000	Revenue: 51952000 Open source
20162016-12-31	Revenue	69337000	Revenue: 69337000 Open source
20172017-12-31	Revenue	71834000	Revenue: 71834000 Open source
20182018-12-31	Revenue	77347000	Revenue: 77347000 Open source
20192019-12-31	Revenue	99219000	Revenue: 99219000 Open source
20202020-12-31	Revenue	66499000	Revenue: 66499000 Open source
20212021-12-31	Revenue	75360000	Revenue: 75360000 Open source
20222022-12-31	Revenue	90214000	Revenue: 90214000 Open source
20232023-12-31	Revenue	94635000	Revenue: 94635000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

4.9% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 51952000 Open source
20162016-12-31	Year over year	33.5%	Revenue: 69337000 Open source Revenue: 51952000 Open source
20172017-12-31	Year over year	3.6%	Revenue: 71834000 Open source Revenue: 69337000 Open source
20182018-12-31	Year over year	7.7%	Revenue: 77347000 Open source Revenue: 71834000 Open source
20192019-12-31	Year over year	28.3%	Revenue: 99219000 Open source Revenue: 77347000 Open source
20202020-12-31	Year over year	-33%	Revenue: 66499000 Open source Revenue: 99219000 Open source
20212021-12-31	Year over year	13.3%	Revenue: 75360000 Open source Revenue: 66499000 Open source
20222022-12-31	Year over year	19.7%	Revenue: 90214000 Open source Revenue: 75360000 Open source
20232023-12-31	Year over year	4.9%	Revenue: 94635000 Open source Revenue: 90214000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3.8% 2023

Net margin -14% 2023

Free cash flow margin -9.8% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-13.4%	Operating Income: -6970000 Open source Revenue: 51952000 Open source
20162016-12-31	Operating margin	-37.2%	Operating Income: -25773000 Open source Revenue: 69337000 Open source
20172017-12-31	Operating margin	-56.1%	Operating Income: -40311000 Open source Revenue: 71834000 Open source
20182018-12-31	Operating margin	16.1%	Operating Income: 12481000 Open source Revenue: 77347000 Open source
20192019-12-31	Operating margin	23.8%	Operating Income: 23630000 Open source Revenue: 99219000 Open source
20202020-12-31	Operating margin	-12.5%	Operating Income: -8342000 Open source Revenue: 66499000 Open source
20212021-12-31	Operating margin	0.5%	Operating Income: 412000 Open source Revenue: 75360000 Open source
20222022-12-31	Operating margin	0.3%	Operating Income: 279000 Open source Revenue: 90214000 Open source
20232023-12-31	Operating margin	-3.8%	Operating Income: -3573000 Open source Revenue: 94635000 Open source
20152015-12-31	Net margin	5.8%	Net Income: 3033000 Open source Revenue: 51952000 Open source
20162016-12-31	Net margin	-43.6%	Net Income: -30205000 Open source Revenue: 69337000 Open source
20172017-12-31	Net margin	-69.7%	Net Income: -50082000 Open source Revenue: 71834000 Open source
20182018-12-31	Net margin	-103.1%	Net Income: -79723000 Open source Revenue: 77347000 Open source
20192019-12-31	Net margin	-18.8%	Net Income: -18630000 Open source Revenue: 99219000 Open source
20202020-12-31	Net margin	-41.4%	Net Income: -27501000 Open source Revenue: 66499000 Open source
20212021-12-31	Net margin	-15.1%	Net Income: -11370000 Open source Revenue: 75360000 Open source
20222022-12-31	Net margin	-22%	Net Income: -19881000 Open source Revenue: 90214000 Open source
20232023-12-31	Net margin	-14%	Net Income: -13274000 Open source Revenue: 94635000 Open source
20152015-12-31	Free cash flow margin	11.6%	Revenue: 51952000 Open source Operating Cash Flow: 8458000 Open source Capital Expenditure: 2411000 Open source
20162016-12-31	Free cash flow margin	-10.1%	Revenue: 69337000 Open source Operating Cash Flow: -3202000 Open source Capital Expenditure: 3770000 Open source
20172017-12-31	Free cash flow margin	19%	Revenue: 71834000 Open source Operating Cash Flow: 19074000 Open source Capital Expenditure: 5403000 Open source
20182018-12-31	Free cash flow margin	4.9%	Revenue: 77347000 Open source Operating Cash Flow: 11022000 Open source Capital Expenditure: 7198000 Open source
20192019-12-31	Free cash flow margin	7.9%	Revenue: 99219000 Open source Operating Cash Flow: 16224000 Open source Capital Expenditure: 8342000 Open source
20202020-12-31	Free cash flow margin	2.5%	Revenue: 66499000 Open source Operating Cash Flow: 9239000 Open source Capital Expenditure: 7603000 Open source
20212021-12-31	Free cash flow margin	7.4%	Revenue: 75360000 Open source Operating Cash Flow: 10858000 Open source Capital Expenditure: 5289000 Open source
20222022-12-31	Free cash flow margin	-13.3%	Revenue: 90214000 Open source Operating Cash Flow: -3644000 Open source Capital Expenditure: 8351000 Open source
20232023-12-31	Free cash flow margin	-9.8%	Revenue: 94635000 Open source Operating Cash Flow: -1005000 Open source Capital Expenditure: 8237000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -1M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	8458000	Operating Cash Flow: 8458000 Open source
20162016-12-31	Operating cash flow	-3202000	Operating Cash Flow: -3202000 Open source
20172017-12-31	Operating cash flow	19074000	Operating Cash Flow: 19074000 Open source
20182018-12-31	Operating cash flow	11022000	Operating Cash Flow: 11022000 Open source
20192019-12-31	Operating cash flow	16224000	Operating Cash Flow: 16224000 Open source
20202020-12-31	Operating cash flow	9239000	Operating Cash Flow: 9239000 Open source
20212021-12-31	Operating cash flow	10858000	Operating Cash Flow: 10858000 Open source
20222022-12-31	Operating cash flow	-3644000	Operating Cash Flow: -3644000 Open source
20232023-12-31	Operating cash flow	-1005000	Operating Cash Flow: -1005000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -9.2M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	6047000	Operating Cash Flow: 8458000 Open source Capital Expenditure: 2411000 Open source
20162016-12-31	Free cash flow	-6972000	Operating Cash Flow: -3202000 Open source Capital Expenditure: 3770000 Open source
20172017-12-31	Free cash flow	13671000	Operating Cash Flow: 19074000 Open source Capital Expenditure: 5403000 Open source
20182018-12-31	Free cash flow	3824000	Operating Cash Flow: 11022000 Open source Capital Expenditure: 7198000 Open source
20192019-12-31	Free cash flow	7882000	Operating Cash Flow: 16224000 Open source Capital Expenditure: 8342000 Open source
20202020-12-31	Free cash flow	1636000	Operating Cash Flow: 9239000 Open source Capital Expenditure: 7603000 Open source
20212021-12-31	Free cash flow	5569000	Operating Cash Flow: 10858000 Open source Capital Expenditure: 5289000 Open source
20222022-12-31	Free cash flow	-11995000	Operating Cash Flow: -3644000 Open source Capital Expenditure: 8351000 Open source
20232023-12-31	Free cash flow	-9242000	Operating Cash Flow: -1005000 Open source Capital Expenditure: 8237000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

61.8% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	70.9%	Total Liabilities: 98347000 Open source Total Assets: 138697000 Open source
20162016-12-31	Liabilities / assets	60.9%	Total Liabilities: 111384000 Open source Total Assets: 182997000 Open source
20172017-12-31	Liabilities / assets	84.5%	Total Liabilities: 157378000 Open source Total Assets: 186226000 Open source
20182018-12-31	Liabilities / assets	112.5%	Total Liabilities: 174993000 Open source Total Assets: 155493000 Open source
20192019-12-31	Liabilities / assets	106.1%	Total Liabilities: 117171000 Open source Total Assets: 110459000 Open source
20202020-12-31	Liabilities / assets	113.6%	Total Liabilities: 117515000 Open source Total Assets: 103415000 Open source
20212021-12-31	Liabilities / assets	73.8%	Total Liabilities: 118253000 Open source Total Assets: 160317000 Open source
20222022-12-31	Liabilities / assets	62%	Total Liabilities: 97584000 Open source Total Assets: 157443000 Open source
20232023-12-31	Liabilities / assets	61.8%	Total Liabilities: 94811000 Open source Total Assets: 153474000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.07× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	4.08×	Current Assets: 38676000 Open source Current Liabilities: 9487000 Open source
20162016-12-31	Current assets / current liabilities	5.21×	Current Assets: 84758000 Open source Current Liabilities: 16261000 Open source
20172017-12-31	Current assets / current liabilities	1.75×	Current Assets: 87283000 Open source Current Liabilities: 49904000 Open source
20182018-12-31	Current assets / current liabilities	2.45×	Current Assets: 71141000 Open source Current Liabilities: 29030000 Open source
20192019-12-31	Current assets / current liabilities	9.28×	Current Assets: 60160000 Open source Current Liabilities: 6485000 Open source
20202020-12-31	Current assets / current liabilities	6.93×	Current Assets: 54069000 Open source Current Liabilities: 7803000 Open source
20212021-12-31	Current assets / current liabilities	3.24×	Current Assets: 57529000 Open source Current Liabilities: 17735000 Open source
20222022-12-31	Current assets / current liabilities	2.44×	Current Assets: 55586000 Open source Current Liabilities: 22808000 Open source
20232023-12-31	Current assets / current liabilities	1.07×	Current Assets: 53461000 Open source Current Liabilities: 49987000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 16.13 million Exact value Exact value: -16134000 USD 2014-01-01 – 2014-12-31: -16134000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2014-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -16134000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16134000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000119312516516045/reph-20151231.xml#80724 Filing: 000119312516516045 The citation records this snapshot. The page link may show a newer release later.	−USD 10.87 million Exact value Exact value: -10867000 USD 2014-01-01 – 2014-12-31: -10867000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2014-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: -10867000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10867000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000119312516516045/reph-20151231.xml#75943 Filing: 000119312516516045 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2015-01-01 – 2015-12-31	USD 3.03 million Exact value Exact value: 3033000 USD 2015-01-01 – 2015-12-31: 3033000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2015-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: 3033000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: 3033000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459018004277/reph-20171231.xml#153860 Filing: 000156459018004277 The citation records this snapshot. The page link may show a newer release later.	USD 8.46 million Exact value Exact value: 8458000 USD 2015-01-01 – 2015-12-31: 8458000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2015-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: 8458000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8458000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459018004277/reph-20171231.xml#179903 Filing: 000156459018004277 The citation records this snapshot. The page link may show a newer release later.	USD 2.41 million Exact value Exact value: 2411000 USD 2015-01-01 – 2015-12-31: 2411000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2015-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 2411000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2411000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459018004277/reph-20171231.xml#180788 Filing: 000156459018004277 The citation records this snapshot. The page link may show a newer release later.	USD 6.05 million Calculation and evidence 8458000 − 2411000 USD Exact free cash flow: 6047000 USD 2015-01-01 – 2015-12-31: 8458000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 2411000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2015-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: 6047000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8458000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459018004277/reph-20171231.xml#179903 Filing: 000156459018004277 Input fundies:CapitalExpenditure: 2411000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459018004277/reph-20171231.xml#180788 Filing: 000156459018004277 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 30.21 million Exact value Exact value: -30205000 USD 2016-01-01 – 2016-12-31: -30205000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2016-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -30205000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30205000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459019003187/reph-20181231.xml#188875 Filing: 000156459019003187 The citation records this snapshot. The page link may show a newer release later.	−USD 3.2 million Exact value Exact value: -3202000 USD 2016-01-01 – 2016-12-31: -3202000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2016-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: -3202000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3202000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459019003187/reph-20181231.xml#216219 Filing: 000156459019003187 The citation records this snapshot. The page link may show a newer release later.	USD 3.77 million Exact value Exact value: 3770000 USD 2016-01-01 – 2016-12-31: 3770000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2016-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 3770000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3770000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459019003187/reph-20181231.xml#216851 Filing: 000156459019003187 The citation records this snapshot. The page link may show a newer release later.	−USD 6.97 million Calculation and evidence -3202000 − 3770000 USD Exact free cash flow: -6972000 USD 2016-01-01 – 2016-12-31: -3202000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 3770000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2016-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: -6972000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3202000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459019003187/reph-20181231.xml#216219 Filing: 000156459019003187 Input fundies:CapitalExpenditure: 3770000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459019003187/reph-20181231.xml#216851 Filing: 000156459019003187 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 50.08 million Exact value Exact value: -50082000 USD 2017-01-01 – 2017-12-31: -50082000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2017-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -50082000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50082000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459020008538/reph-20191231.xml#151977 Filing: 000156459020008538 The citation records this snapshot. The page link may show a newer release later.	USD 19.07 million Exact value Exact value: 19074000 USD 2017-01-01 – 2017-12-31: 19074000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2017-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: 19074000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 19074000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459020008538/reph-20191231.xml#185109 Filing: 000156459020008538 The citation records this snapshot. The page link may show a newer release later.	USD 5.4 million Exact value Exact value: 5403000 USD 2017-01-01 – 2017-12-31: 5403000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2017-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 5403000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5403000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459020008538/reph-20191231.xml#185780 Filing: 000156459020008538 The citation records this snapshot. The page link may show a newer release later.	USD 13.67 million Calculation and evidence 19074000 − 5403000 USD Exact free cash flow: 13671000 USD 2017-01-01 – 2017-12-31: 19074000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 5403000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2017-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: 13671000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 19074000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459020008538/reph-20191231.xml#185109 Filing: 000156459020008538 Input fundies:CapitalExpenditure: 5403000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459020008538/reph-20191231.xml#185780 Filing: 000156459020008538 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 79.72 million Exact value Exact value: -79723000 USD 2018-01-01 – 2018-12-31: -79723000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2018-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -79723000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -79723000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459021009198/reph-10k_20201231.htm#1501123 Filing: 000156459021009198 The citation records this snapshot. The page link may show a newer release later.	USD 11.02 million Exact value Exact value: 11022000 USD 2018-01-01 – 2018-12-31: 11022000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2018-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: 11022000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 11022000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459021009198/reph-10k_20201231.htm#1778140 Filing: 000156459021009198 The citation records this snapshot. The page link may show a newer release later.	USD 7.2 million Exact value Exact value: 7198000 USD 2018-01-01 – 2018-12-31: 7198000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2018-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 7198000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7198000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459021009198/reph-10k_20201231.htm#1788548 Filing: 000156459021009198 The citation records this snapshot. The page link may show a newer release later.	USD 3.82 million Calculation and evidence 11022000 − 7198000 USD Exact free cash flow: 3824000 USD 2018-01-01 – 2018-12-31: 11022000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 7198000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2018-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: 3824000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 11022000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459021009198/reph-10k_20201231.htm#1778140 Filing: 000156459021009198 Input fundies:CapitalExpenditure: 7198000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000156459021009198/reph-10k_20201231.htm#1788548 Filing: 000156459021009198 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 18.63 million Exact value Exact value: -18630000 USD 2019-01-01 – 2019-12-31: -18630000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2019-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -18630000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18630000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017022002545/reph-20211231.htm#1559476 Filing: 000095017022002545 The citation records this snapshot. The page link may show a newer release later.	USD 16.22 million Exact value Exact value: 16224000 USD 2019-01-01 – 2019-12-31: 16224000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2019-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: 16224000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 16224000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017022002545/reph-20211231.htm#1804742 Filing: 000095017022002545 The citation records this snapshot. The page link may show a newer release later.	USD 8.34 million Exact value Exact value: 8342000 USD 2019-01-01 – 2019-12-31: 8342000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2019-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 8342000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8342000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017022002545/reph-20211231.htm#1819378 Filing: 000095017022002545 The citation records this snapshot. The page link may show a newer release later.	USD 7.88 million Calculation and evidence 16224000 − 8342000 USD Exact free cash flow: 7882000 USD 2019-01-01 – 2019-12-31: 16224000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 8342000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2019-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: 7882000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 16224000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017022002545/reph-20211231.htm#1804742 Filing: 000095017022002545 Input fundies:CapitalExpenditure: 8342000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017022002545/reph-20211231.htm#1819378 Filing: 000095017022002545 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 27.5 million Exact value Exact value: -27501000 USD 2020-01-01 – 2020-12-31: -27501000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2020-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -27501000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27501000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017023005586/sctl-20221231.htm#1576189 Filing: 000095017023005586 The citation records this snapshot. The page link may show a newer release later.	USD 9.24 million Exact value Exact value: 9239000 USD 2020-01-01 – 2020-12-31: 9239000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2020-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: 9239000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 9239000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017023005586/sctl-20221231.htm#1878567 Filing: 000095017023005586 The citation records this snapshot. The page link may show a newer release later.	USD 7.6 million Exact value Exact value: 7603000 USD 2020-01-01 – 2020-12-31: 7603000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2020-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 7603000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7603000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017023005586/sctl-20221231.htm#1895770 Filing: 000095017023005586 The citation records this snapshot. The page link may show a newer release later.	USD 1.64 million Calculation and evidence 9239000 − 7603000 USD Exact free cash flow: 1636000 USD 2020-01-01 – 2020-12-31: 9239000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 7603000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2020-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: 1636000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 9239000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017023005586/sctl-20221231.htm#1878567 Filing: 000095017023005586 Input fundies:CapitalExpenditure: 7603000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017023005586/sctl-20221231.htm#1895770 Filing: 000095017023005586 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 11.37 million Exact value Exact value: -11370000 USD 2021-01-01 – 2021-12-31: -11370000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2021-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -11370000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11370000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1211816 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	USD 10.86 million Exact value Exact value: 10858000 USD 2021-01-01 – 2021-12-31: 10858000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2021-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: 10858000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 10858000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1409586 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	USD 5.29 million Exact value Exact value: 5289000 USD 2021-01-01 – 2021-12-31: 5289000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2021-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 5289000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5289000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1420224 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	USD 5.57 million Calculation and evidence 10858000 − 5289000 USD Exact free cash flow: 5569000 USD 2021-01-01 – 2021-12-31: 10858000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 5289000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2021-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: 5569000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 10858000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1409586 Filing: 000095017024035480 Input fundies:CapitalExpenditure: 5289000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1420224 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 19.88 million Exact value Exact value: -19881000 USD 2022-01-01 – 2022-12-31: -19881000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2022-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -19881000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19881000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1261578 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	−USD 3.64 million Exact value Exact value: -3644000 USD 2022-01-01 – 2022-12-31: -3644000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2022-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: -3644000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3644000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1408205 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	USD 8.35 million Exact value Exact value: 8351000 USD 2022-01-01 – 2022-12-31: 8351000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2022-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 8351000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8351000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1418772 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	−USD 12 million Calculation and evidence -3644000 − 8351000 USD Exact free cash flow: -11995000 USD 2022-01-01 – 2022-12-31: -3644000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 8351000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2022-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: -11995000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3644000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1408205 Filing: 000095017024035480 Input fundies:CapitalExpenditure: 8351000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1418772 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 13.27 million Exact value Exact value: -13274000 USD 2023-01-01 – 2023-12-31: -13274000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Net Income: -13274000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13274000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1328050 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	−USD 1.01 million Exact value Exact value: -1005000 USD 2023-01-01 – 2023-12-31: -1005000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Operating Cash Flow: -1005000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1005000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1516229 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	USD 8.24 million Exact value Exact value: 8237000 USD 2023-01-01 – 2023-12-31: 8237000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Capital Expenditure: 8237000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8237000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1417355 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.	−USD 9.24 million Calculation and evidence -1005000 − 8237000 USD Exact free cash flow: -9242000 USD 2023-01-01 – 2023-12-31: -1005000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 8237000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Recro Pharma, Inc. · 2023-12-31 Recro Pharma, Inc. (edgar:1588972) Free cash flow: -9242000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:20:14Z Snapshot: 81b02af1b3b51dcbc10c4d6d9d03e5aaa5470776868a8c257d439507b6225ff2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1588972?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1005000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1516229 Filing: 000095017024035480 Input fundies:CapitalExpenditure: 8237000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1588972/000095017024035480/sctl-20231231.htm#1417355 Filing: 000095017024035480 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

92 filings · 3,293 latest values · 3,293 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001588972, 1588972, REPH, SCTL, edgar:1588972

Also known as Recro Pharma, Inc., Societal CDMO, Inc.

Recro Pharma, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation